Tirzepatide While Breastfeeding: What the Breast Milk Study and the Label Actually Show

Tirzepatide during breastfeeding is a decision that rests on real data in one area and real gaps in another. In the only dedicated study, a single 5 mg dose given to 11 lactating women left tirzepatide undetectable in 164 of 171 breast milk samples, and the total amount found added up to less than 0.02% of the mother's dose. What that study could not tell anyone is how tirzepatide affects a breastfed baby or a mother's milk supply, because no one has measured either.

That combination explains why the Zepbound label stops short of calling the medicine safe or unsafe during breastfeeding and instead asks the prescriber and the parent to weigh the benefits of breastfeeding against the mother's need for treatment.

Can someone take tirzepatide while breastfeeding?

Tirzepatide is not listed as contraindicated during breastfeeding, although its safety for breastfed infants has not been established. The prescribing information says the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for the medicine and any potential effects on the infant. The patient Medication Guide puts it more plainly, noting that Zepbound may pass into breast milk and that patients should talk with their healthcare provider about the best way to feed the baby while using it (Zepbound prescribing information, DailyMed, 2026).

Expert groups lean more cautious than the label. A 2026 international scoping review and consensus paper in Obesity Reviews notes that current guidance treats breastfeeding on incretin based medicines as contraindicated, and only one of the studies it identified addressed lactation (Maslin et al., Obesity Reviews, 2026). The European Association for the Study of Obesity also states that clinical data on the safety of obesity medication during lactation are limited (EASO position statement, Obesity Facts, 2025).

How much tirzepatide gets into breast milk?

Very little tirzepatide reached breast milk after a single 5 mg dose. According to the lactation section of the Zepbound label, 11 healthy lactating women received one injection under the skin and gave milk samples over the following 28 days. Of 171 samples, 164 had no detectable tirzepatide on an assay with a limit of detection of 4 ng/mL, while the remaining 7 held a combined amount equal to less than 0.02% of the dose the mother received. The last measurable concentration appeared 5 days after the injection, and so few samples had measurable drug that the researchers could not calculate total milk exposure.

Large protein based drugs generally pass poorly into milk, and a related medicine shows a similar pattern: in a Texas Tech study of milk from eight women taking semaglutide, the drug was not detected in any sample, and the worst case relative infant dose was estimated at 1.26%, well under the 10% level often used as a rough threshold (Diab et al., Nutrients, 2024). Because semaglutide is a different molecule, that result supports the general picture without standing in for tirzepatide data.

What did the breast milk study leave unanswered?

The lactation study answered one narrow question about drug levels in milk after a single dose, leaving several larger questions open.

It used one dose rather than weekly treatment. Tirzepatide is taken once a week and has an elimination half life of approximately 5 to 6 days, according to the label, so the drug builds up over the first weeks of dosing before blood levels level off. A single dose study cannot show what milk levels look like after that buildup. Our guide to tirzepatide's weekly rhythm explains the cycle.

It used a starting range dose. The study dose was 5 mg, while many people on tirzepatide for weight management move up to higher weekly doses, and milk levels at those doses have not been reported.

It measured milk rather than babies. No study has followed breastfed infants of mothers taking tirzepatide for feeding, weight gain, blood sugar or growth. That gap matters most for newborns and premature babies.

It did not measure milk supply. Tirzepatide reduces appetite and food intake, and making milk requires energy, fluid and nutrients. Whether eating noticeably less on tirzepatide changes milk volume or composition has not been studied.

What do recent reviews say about GLP-1 medicines and breastfeeding?

Recent reviews agree that the lactation evidence is thin across the whole drug class rather than for tirzepatide alone. A 2026 systematic review in Diabetes, Obesity and Metabolism pooled 36 studies of GLP-1 and dual GLP-1/GIP medicines around conception, pregnancy and lactation, and it found the lactation data sparse, with one pharmacokinetic study reporting no detectable semaglutide in human milk (Ozbek et al., 2026).

A second 2026 systematic review, in Clinical Pharmacology and Therapeutics, looked at diabetes medicines and breast milk more broadly and found that only 5 of 20 drugs had any human data on transfer into milk (Richardson et al., 2026). Most of the guideline recommendations it examined advised against using glucose lowering medicines while breastfeeding, yet very few of those recommendations rested on clinical evidence. Much of that caution reflects missing data rather than evidence of harm, which is still a legitimate reason for care with a young infant.

Why are more new parents asking about tirzepatide?

Postpartum GLP-1 prescribing has climbed quickly in the United States. A 2026 study in Obstetrics and Gynecology found that semaglutide and tirzepatide prescriptions in the year after delivery rose from 0.3 to 14.6 per 1,000 deliveries between 2019 and 2024, and the authors concluded that the trend highlights the need for safety data in this period (Lessard et al., Obstetrics and Gynecology, 2026).

What should a breastfeeding parent discuss with a prescriber?

A careful prescriber will usually want to work through several factors before tirzepatide is started during breastfeeding:

• The baby's age and health. A premature or very young infant presents a different situation from an older baby who eats solid food and nurses less often.
• The reason for treatment now. Type 2 diabetes with poor blood sugar control is a different clinical need from wanting to lose pregnancy weight, and some people choose to wait until after weaning.
• Nutrition and hydration. Tirzepatide can make under eating easy while breastfeeding raises the stakes on protein, fluids and micronutrients, as covered in our guides on what to eat on tirzepatide and signs of under fueling.
• What to watch for in the baby. If treatment goes ahead, it helps to agree in advance which changes in feeding, alertness, diapers or weight gain should prompt a call to the pediatrician.

How does tirzepatide affect postpartum contraception?

Tirzepatide may reduce the effectiveness of oral hormonal contraceptives, according to the Zepbound label, which advises switching to a contraceptive that is not taken by mouth, or adding a barrier method, for 4 weeks after starting and for 4 weeks after each dose increase. The label also states that weight loss offers no benefit during pregnancy and that Zepbound should be stopped once a pregnancy is recognized. Our guide to tirzepatide, contraception and fertility covers the details.

Frequently Asked Questions

The Bottom Line

The one study that has measured tirzepatide in breast milk is reassuring about how little of the drug gets in, since it was undetectable in 164 of 171 samples after a single 5 mg dose. The same study is silent on what matters most to parents, which is how a baby and a milk supply respond over weeks of treatment. Until that is studied, tirzepatide during breastfeeding remains an individual decision best made with a prescriber who knows both the mother's and the baby's situation.